IncellDx and MD Biosciences sign definitive agreement for commercialization of COVID-19 / Cytokine Storm Cytokine Panel and CCR5 Receptor Occupancy in US and EU.


San Carlos, California., September 15, 2020 / PRNewswire / – IncellDx, Inc., a global leader in single-cell diagnostics, announces the signing of an agreement with MD Biosciences, Inc. to commercialize novel assays based on Inkeldex’s work in diagnostics, prognologists and therapeutic biomarkers. is. COVID-19 and other cytokine storm conditions.

Under the terms of the agreement, MD Biosciences, a major world-wide laboratory provider of esoteric immune-based testing, will validate and initiate laboratory testing offerings in the US and the European Union to measure levels of cytokines related to COVID / Cytocom Storm. Those who are highly elevated in patients with COVID-19 and often remain uncommon in patients recovering from COVID-19, but still suffer from symptoms. These patients are known as “long-lasting”.

“We are thrilled to partner with MD Biosciences after our successful working relationship over the past year,” Dr. Bruce paterson, CEO of IncellDx We are excited to offer standardized solutions for cytokine and immunology testing in partnership with MD Biosciences’ CLIA certified reference laboratories in the US. Europe. We are happy to receive these solutions prior to cytokine storm-related therapeutics approval, and in the short term, are focused on helping COVID-19 patients who are still experiencing symptoms long after diagnosis Are suffering – the so-called long-thin. For that effort, we will establish a COVID-19 long-term diagnosis and treatment initiative with a multi-disciplinary approach to improve the lives of people with long-term symptoms. ”

Deals with MD Biosciences include receptor occupancy aces for CCR5-directed therapeutics, a promising target in the fight against COVID-19 and possibly other “cytokine storm” related conditions.

“This is a very exciting opportunity for us,” Dr. Eddie moreadian, CEO of MD Biosciences. “COVID-19, associated cytokine storms in patients, and potential long-term effects have changed many aspects of healthcare, both in the context of patients as well as clinical studies. IncellDx’s newly developed panel will be an important contribution. For patient management. We look forward to providing meaningful help in combating the effects of this infection and improving the patient’s life and clinical outcomes. ”

IncellDx, Inc. about
IncellDx, Inc., is located in San Carlos, California, A molecular diagnostics company dedicated to revolutionizing healthcare, one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, the company’s focus is on COVID-19, the most serious diseases in the areas of infectious disease and oncology, particularly diseases of the cervix, head and neck, lungs, bladder, breast and prostate cancer. But there is danger.

About MD Biosciences
MD Biosciences, Inc. Is a leading clinical laboratory that provides diagnostic assay services for clinical trials through its own network of laboratories as well as related laboratories. Europe And other parts of the world. MD Biosciences provides highly complex assays for biomarker and biomarker panels and identifies disease progression in clinical trials, particularly in the presence and absence of therapy, for the study of cutting-edge therapeutic candidates.

for more information contact:
Contact: Ronald A. Blum, PhD, Chief Marketing Officer, Inkeldex
[email protected]

Please visit http://incelldx.com/

Source IncellDx, Inc.

Related Links

https://incelldx.com/

    .